Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2979MR)

This product GTTS-WQ2979MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2979MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11272MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ11696MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ9291MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ306MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ15896MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ13605MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ10121MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ3948MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW